re: Ann: Appointment of Managing Director to ...
“Commercially and scientifically he has an exemplary background, bringing valuable doctoral qualifications in molecular oncology and deep commercial biotechnology experience particularly in partnerships, M&A and licensing agreements with global pharmaceutical companies. This is a pivotal appointment for our Company.”
Dr Crombie commented: “Virax has an outstanding technical portfolio emanating from some of the best oncology centers in the United States and Australia.
The novel oncology assets recently acquired from Yale University via the Pathway Oncology acquisition will allow us to target several cancer indications including multiple myeloma and breast cancer.
Further, Virax’s existing Co-X-GeneTM technology provides proven gene therapeutic approaches to target other cancer indications.”
“I look forward to leading Virax and pursuing the development of these valuable technologies clinically and commercially. We will seek to commence clinical trials at the earliest opportunity.
VHL Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)